The pyridinyl imidazole cytokine-suppressing anti-inflammatory drug (CSAID(TM)), SB 206718 (1) was required in I-125-labeled form for photoaffinity ligand studies. The target compound (SE 206718-[I-125], [I-125]1) was obtained via conversion of the highly functionalized 1 to a tributylstannyl derivative. Radioiododestannylation using (NaI)-I-125 in the presence of chloramine-T gave good radiochemical yields of the title compound (42-69%, four radiosyntheses) at high radiochemical purity (>98%) after HPLC purification at specific activities of 1670-1736 Ci/mmol.